Almirall's Q3: Soaring Shares, Ebglyss Potential
Update: 2025-11-10
Description
Almiralls Q3 financial results exceed expectations, boosting shares by over 8%. EBIT of €67.4M, net income of €39.1M, and total revenue of €825.6M drive the positive performance. Key products like Ebglyss and Ilumetri contribute significantly, while Klisyri falls short. Almirall reaffirms 2025 outlook, projecting net sales growth of 10-13% and EBITDA of €220-240M. Jefferies analysts maintain a Buy rating, citing Ebglyss potential as a preferred first-line treatment in Europe.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
